Daniel Lifveredson is leaving LIDDS’ Board of Directors

Regulatory

UPPSALA, SWEDEN – LIDDS announces today that Daniel Lifveredson has informed the company that he is leaving the board at his own request. The decision is based on disagreement about the company's strategic direction.

The company's board therefore consists of Pontus Ottosson (chairman), David Bejker and Johan Lund. According to LIDDS' articles of association, the board must consist of a minimum of three and a maximum of ten members, and the board thus fulfills the requirements of the articles of association also after Daniel Lifveredson's resignation.

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-12-07 08:33 CET.

Attachments

Daniel Lifveredson is leaving LIDDS’ Board of Directors